BioLynx (China) Overview

  • Founded
  • 2015
  • Status
  • Private
  • Latest Deal Type
  • Series A
  • Investors
  • 4

BioLynx (China) General Information


Provider of antibody research and development. The company's self-developed next-generation antibody development platform, the recombinant rabbit monoclonal antibody technology platform (R2mAb ® Platform) has high specificity, sensitivity, stability, and is specially suitable for corporate customers with high antibody quality requirements and sensitivities between antibody batches.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Drug Discovery
Primary Office
  • Room 1303, Building 5,Tianhe Hi-Tech Industrial Park
  • No. 688 Bin'an Road, Binjiang District
  • Hangzhou, Zhejiang 310052
  • China
+86 0571 0000 0000
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

BioLynx (China) Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Early Stage VC (Series A) 10-Apr-2018 Completed Startup
1. Seed Round Completed
To view BioLynx (China)’s complete valuation and funding history, request access »

BioLynx (China) Executive Team (1)

Name Title Board Seat Contact Info
Jinfeng Lu Founder
To view BioLynx (China)’s complete executive team members history, request access »

BioLynx (China) Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Puhua Capital Venture Capital Minority 000 0000 000000 0
BioClub Venture Capital Minority 000 0000 000000 0
Guohong Zhizhen Venture Capital Minority 000 0000 000000 0
Share Capital Venture Capital Minority 000 0000 000000 0
To view BioLynx (China)’s complete investors history, request access »